Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18353906 | 0.91 | MEN1 (0.33) | TSHRALOX5 | |
| SCHEMBL30457985 | 0.89 | EPHX1 (0.40) | TSHR | |
| SCHEMBL30457924 | 0.89 | EPHX1 (0.40) | TSHR | |
| SCHEMBL2381945 | 0.89 | EPHX1 (0.40) | TSHR | |
| SCHEMBL19209623 | 0.86 | ALOX5 (0.38) | TSHRALOX5CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL8295291 | 0.83 | TSHR (0.35) | TSHRALOX5CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL19574085 | 0.80 | EPHX2 (0.32) | — | |
| SCHEMBL8249586 | 0.78 | SLC7A5 (0.39) | TSHRALOX5 | |
| SCHEMBL1157143 | 0.77 | — | — | |
| SCHEMBL1157146 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116194144-A | Prodrugs of phosphoramide nucleotide analogs and pharmaceutical uses thereof | 吉利德科学公司 | 2023-05-30 | — | — | CN | disclosed |
| US-8362248-B2 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20100113480-A1 | PROCESS FOR THE PREPARATION OF TRI-SUBSTITUTED PYRIDINE AND TRI-SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL AS GDIR AGONISTS | ARENA PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20100113479-A1 | PROCESS FOR THE PREPARATION OF TRI-SUBSTITUTED PYRIDINE AND TRI-SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL AS GDIR AGONISTS | ARENA PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070167473-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070078150-A1 | Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078150-A1 | Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | PC, GPR119, PNPO | TSHR 1805/4885ALOX5 678/4885CHRNB2 4756/4885 |
| US-20070167473-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | PLPBP, PNPO, PDXK | TSHR 1399/4885ALOX5 347/4885CHRNB2 4279/4885 |
| US-20100113479-A1 | PROCESS FOR THE PREPARATION OF TRI-SUBSTITUTED PYRIDINE AND TRI-SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL AS GDIR AGONISTS | GPR119, GCGR, GIPR | TSHR 21/4885ALOX5 2316/4885CHRNB2 1800/4885 |
| US-20100113480-A1 | PROCESS FOR THE PREPARATION OF TRI-SUBSTITUTED PYRIDINE AND TRI-SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL AS GDIR AGONISTS | GPR119, GCGR, GIPR | TSHR 21/4885ALOX5 2316/4885CHRNB2 1800/4885 |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | TSHR 1418/4885ALOX5 322/4885CHRNB2 3419/4885 |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | TSHR 450/4885ALOX5 2125/4885CHRNB2 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.